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Opinion statement
Within the last 2 years the bulk of information on evidence based treatments in ADHD
was reviewed quite intensively and new empirical studies could be added. This update
reports comprehensively about actual and essential facts in the field related to brain
development and sensitive periods, predictors of treatment, safety of medication, val-
ue of naturalistic studies, new drugs and complementary medicine, behavioral inter-
ventions including neurofeedback and psychosocial treatment, treatment of
comorbidity, and ethical considerations including preventive aspects. The updated
combination of well selected evidence based treatments (ie, pharma plus non-pharma)
seems to be clinically and ethically recommended as also suggested by the European
and American guidelines on ADHD.
Introduction
A bulk of empirical information
Attention deficit hyperactivity disorder (ADHD) is one
of the most common (worldwide prevalence of about
5%) [1]; anddebilitating child psychiatric disorderswith
the core symptoms of inattention, hyperactivity, and im-
pulsivity. Also a high frequency of co-existing develop-
mental psychopathological conditions (eg, anxiety, de-
pression, tics, autism, and oppositional behavior) may
lead to psychosocial impairment and often need to be
treated. Treatment programs usually includemedication
and psychosocial interventions [2].
From the year 2011 to 2012, several reviews and
meta-analyses covered the field of treatment
options in ADHD and their degree of empirical ev-
idence (eg, [3•, 4••, 5, 6••, 7•, 8•, 9] European
ADHD Guidelines Group [EAGG] submitted). Also,
the actual clinical practice guidelines for ADHD of
the American Academy of Pediatrics appeared in
2011 [10••].
Hence, this review intends to comment on the con-
clusions of the reviews and give an update on some
neglected but important issues of pharmacological
and non-pharmacological treatment options of ADHD
like prevention and ethics.
Treatment
Neurodevelopmental aspects of interventions
Whatever the treatment for ADHD is, to be successful it must change the
function (and probably also the structure) of the child’s brain. Within the last
few years we learned from experiments of ADHD on animal models that
stimulants may bring the increased density of dopamine transporters back to
a normal range [11]. Moreover, in an Annual Research Review on develop-
mental neuropharmacology, Andersen and Navalta [12•] reported systemi-
cally how currently used psychotropic agents in ADHD (like stimulants and
atomoxetine) might influence long-term brain maturation; especially, when
given during sensitive periods like pre-puberty. This is supported by Roessner
et al. [11] for methylphenidate and an animal study on reboxetine by Bock et
al. [13]. Further investigations are necessary before one might think of early
drug intervention in ADHD in order to stop its progression and prevent
symptoms from manifesting in the long-run.
However, some recent clinical investigations give hope. For example,
Hoekzema et al. [14] assessed “whether a cognitive training program ap-
plied to ADHD patients can contravene some of the associated neuroana-
tomical alterations”. Indeed, they observed MRI volumetric increase in
frontal cortex and cerebellum concluding that cognitive training induced
neuroanatomical plasticity. Further, Nakao et al. [15] conducted a voxel-
based meta-analysis comprising 278 patients with ADHD and 344 healthy
subjects (children and adults) exploring the association of stimulant medi-
cation and gray matter volume. Their positive finding in the basal ganglia
suggests that ADHD patients may progressively catch up with their devel-
opmental delay, especially when they are treated with stimulant medication.
In summary, pharmacological as well as non-pharmacological interven-
tions in ADHD seem to support developmental normalization and/or
compensation of brain alterations in these patients. The chance may be
highest during sensitive phases of neuronal plasticity. Thus there might be a
potential for secondary prevention in case of early detection of ADHD.
Predictors of treatment
A very early start of treatment should qualify for a safe use. Unfortunately,
clear predictors for this and successful symptom reduction are lacking. At the
moment pharmacogenetic approaches are en vogue, but before the field can
offer data to be used for personalized ADHD treatment, pharmacogenetic
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studies with larger samples and range of outcomes related to efficacy, effec-
tiveness, and safety are needed to determine the utility of genomic infor-
mation [16]). Their data and methodological limitations allowed only a
rough conclusion, namely “that DAT and DRD4 polymorphisms may be
associated with individual variability in MPH dose-response”. Markers of the
dopaminergic system may be the most promising candidates for a person-
alized pharmacogenetic approach to date, but such a pharmacologic man-
agement of ADHD is not near.
Concerning non-genetic predictors, probably the prepotent response inhi-
bition reaction time in a neuropsychological Stop-Signal-Task seems a good
candidate. Children with lower levels of inhibition showed worse outcome
after 10 weeks of MPH treatment, independent of dose [17].
Finally, success of neurofeedback training (NF) is the better the higher the
pre-NF-training amplitude of the contingent negative variation (CNV); the
latter is an event-related electrophysiological brain potential generated
mainly by anterior cingulate cortex [ACC]) [18].
Hence, preparation for and inhibition of a goal directed behavior is relat-
ed to the dopaminergic genes [19] and thus indicators of the latter should be
evaluated further as predictors for treatment in ADHD.
Medication and safety
Treatment options for ADHD are always lively debated in light of probable
side effects, especially if medication with stimulants is considered. Fortu-
nately, guidelines help clinicians to provide high-quality care to their patients
by delivering evidence-based treatment programs.
The European ADHD Guidelines Group (EAGG) reviewed the published
literature on adverse effects of the drugs that are licensed in Europe in order
to treat ADHD [20••] (an updated and very practical version of this topic will
appear soon and comes to a similar conclusion). They reported on cardiac
adverse events, suicide-related events, growth in childhood, sleep distur-
bances, tics and Tourette’s syndrome, substance abuse and misuse and di-
version, epilepsy and seizures, psychotic symptoms, drug holidays, sudden
death, liver-failure, and long-term changes in the brain. They conclude, that
“for many clinicians, the balance of risks against possible benefits of treat-
ment will be seen as favorable in most cases”.
Especially, because of critical reports, cardiovascular risks were investigat-
ed and reviewed very thoroughly [21–25]. Stimulants are increasing norad-
renergic and dopaminergic transmission and thus via sympathomimetic
effects increase blood pressure of about 5 mm Hg and heart rate of about 10
beats/minute. Usually, this does not change electrocardiographic parameters
and risk for cardiovascular events. However, about 5 %–15 % of children
may show greater increases and/or report cardiovascular complaints [23].
Therefore, to prevent adverse events, the physician should follow the clinical
recommendations of societies and guideline groups for screening and
monitoring of cardiovascular disease/complaints in children and adolescents
treated with stimulants and noradrenergic drugs like atomoxetine, clonidine,
and guanfacine. In cases of uncertainties an assessment by and shared-care
with a pediatric cardiologist is recommended [24]. This is in line with a re-
cent public health study on private insurance data of 171,126 6–21 year old
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subjects without known cardiovascular risk factors. Clinical diagnosis of
cardiovascular events and symptoms were rare and not associated with
stimulant use for an average follow-up of 1 year 9 months [22]. Also, Vitiello
et al. [25] conducted a secondary analysis of the MTA-study on blood pres-
sure and heart rate over 10 years. No symptomatic cardiovascular event
leading to medical attention was reported. They conclude that stimulant
treatment did not increase the risk for prehypertension or hypertension, not
even in a subset of the patients. The effect on heart rate was driven by current
use of stimulants reflecting chances for reversibility to normal. All in all,
reviews and new data give evidence for a detectable adrenergic cardiovascular
effect even after years of treatment with stimulants, but with careful moni-
toring this should not lead to clinical problems. However, in order to further
elucidate the long-term cardiovascular and other effects a publicly funded
ADHD Drug Use Chronic Effects (ADDUCE) study was recently launched in
Europe.
A second important and still debated point of safety is children’s growth.
Dura-Trave et al. [26] measured weight and height in 187 ADHD children
treated with OROS-MPH (about 8 years of age at the beginning) during
4 years of follow-up. Mean weight and height values (in absolute terms)
increased slightly over time (14.9 kg and 19.8 cm) reaching age appropriate
group values for both weight and height after 48 months. However, it
remains to be discussed if an observed transitory growth deficit might be best
explained by transitional nutritional aspects, which may disappear under the
long-term treatment with stimulants and thus the final stature measures may
be reached. Since these are group effects, some children may not show such a
spontaneous recovery. Hence, careful monitoring, nutritional optimization,
and drug holidays should be considered within an individual/personalized
drug treatment plan for prevention of final weight and height deficits.
Value of naturalistic studies
Randomized controlled trials (RCTs) are the gold standard in order to clarify
the efficacy of an intervention. Post-RCT observational studies are required to
ensure well-monitored, up-to-date treatment management regarding effec-
tiveness (“is it of use?”), and efficiency (“how much benefit at what cost?”),
especially for a long-term perspective [27]. Today, collecting, reporting and
interpreting data from naturalistic studies is still heterogeneous. It follows,
that the value of such urgently needed studies is mixed.
Concerning pharmacological treatment of ADHD observational studies
contributed a great deal to the improvement of daily clinical practice. Al-
though it is not yet clear from the naturalistic part of the MTA-study, what
treatment contributed what in the long run [17, 28] some more recent ob-
servational trials could indicate that switching from one MPH preparation to
another, either from MPH-IR to MPH-MR or even from one MPH-MR for-
mulation to another, appears to be a valid clinical approach. The improve-
ment might be best explained by (1) increased/optimized dose of MPH, (2)
shorter intervals between visits, (3) positive expectation of improvement,
and (4) improvement of adherence in the long-term [27].
Finally, van der Oord et al. [17] pointed out that in a naturalistic follow-
up of 24 ADHD children over 4.5 to 7.5 years treatment with behavior
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therapy next to MPH may not have additive effects on short-term outcome,
but may cause long-term effects, ie, less methylphenidate use in adolescence.
If this is proven to be true by future evidence, such a combined treatment
might reflect, economically and ethically, an improvement of ADHD treat-
ment, including the prevention of side effects by medication.
Drugs and complementary medicine
There is no break-through for treatment of ADHD expected within the short-
term, but the new recommendations of the American Academy of Pediatrics
[10••] are helpful and quite close to the European Guidelines [2, 28], ie, for
preschool children (4–5 years of age) behavior therapy is first-line, and MPH
second-line; for elementary school-aged children (6–11 years of age) both,
behavior therapy and/or medication should be prescribed—preferably both.
Drugs recommended are stimulants, atomoxetine, extended-release guanfa-
cine, and extended-release clonidine (in that order). For adolescents (12–
18 years of age) recommendations are similar and assent of the youngster is
underlined.
In clinical practice, the different drugs in use are sometimes administered
adjunctively, without having a controlled evidence base for this. For the
combined application of guanfacine XR plus stimulants, Wilens et al. [29]
showed a significantly greater improvement over placebo plus stimulant in
ADHD symptoms and generated no new safety signals. A drug not yet
mentioned in the guidelines but already in clinical use and promising is
lis-dexamfetamine (LDX). LDX is a pro-drug, which means that lysin is
pharmacologically coupled with dexamfetamine and absorbed as the
combination. In the blood both parts are metabolically separated by
enzymatic hydrolysis and only now dexamfetamine can act at the neu-
ronal cells as a stimulant. Due to the rate-limiting nature of hydrolysis,
the toxicity potential, and risks of overdose are reduced. This special
situation decreases the risks for misuse and diversion of this pro-drug
[30]. Two recent studies [31, 32] inform us that LDX seems to be a safe
and efficacious treatment for symptom relief in ADHD. All doses (30,
50, 70 mg) in the short-term (4–5 weeks) were efficacious vs placebo
and demonstrated an acceptable safety profile as already known from
other LDX-studies.
For the practitioner it would be important to know from the beginning,
what stimulant or noradrenergic drug may be the best one to support the
patient. This predictive approach is limited since, so far, individual predictors
(like CNV and certain gene-profiles) only predict treatment outcome in
general, but not for a specific drug or intervention. Also, recent comparisons
of Medikinet-R vs Concerta [33] and between extended-release dexmethyl-
phenidate vs extended-release mixed amphetamine salts [34], as well as a
meta-analysis of MPH vs atomoxetine [5] came to similar/non-inferior effi-
cacy, and acceptability when similar doses were given. This weakens the in-
dividualized predictive approach and supports the recommendations of the
existing clinical guidelines.
Finally, co-existing sleep problems in ADHDmay complicate family inter-
action at home and increase sleepiness during the day. So far, melatonin is
often used off-label in order to reorganize the disturbed circadian rhythm. A
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first RCT on the effect of l-theanine on objective sleep quality (using actig-
raphy) in 98 ADHD boys aged 8–12 years demonstrated that 400 mg daily of
l-theanine might improve some aspects of sleep quality but more rigorous
studies are needed.
Complementary medicine in ADHD (electrolytes, restriction diet, food
color additives, and omega-3 fatty acid) is again in the focus of ADHD
treatment options.
While some news about zinc and iron [35, 36•] needs to be better sub-
stantiated, a meta-analysis on restriction diet and synthetic food color
additives offers some helpful and clarifying evidence [6••]. Within the last
years, subsequent studies appeared leading to divergent conclusions on the
risks of food colors and the practical value of restriction diets. Overall, Nigg
et al. [6••] drew a mixed conclusion: “Although the evidence is too weak to
justify action recommendations, absent a strong precautionary stance, it is
too substantial to dismiss” (p. 96). An estimated 8 % of children with ADHD
may have symptoms related to synthetic food colors, some of which being
responsive to restriction diet. However, effect sizes can be found only be-
tween 0.12 and 0.27 (depending on the source of information like parents,
teacher, physician, attention-test) and are far behind that what is known
from medication (about 0.7–0.9) and behavior therapy (about 0.5). One
should remain critical against restriction diet, although a strictly super-
vised restriction elimination diet may be a valuable instrument to assess
whether ADHD is induced by food [37•]; (remark: this study was re-
moved as outlier by Nigg et al. [6••] because of weak blinding and
unexpected high effect sizes). A recent review on the role of dietary
methods for ADHD focuses on efficacy and practice while concluding
that additive-free and oligoantigenic/elimination diets are time-consum-
ing and disruptive to the household [38].
Hence, adherence problems are foreseeable even if indication is given
only in selected patients, contradicting Pelsser et al. [37•] who “think
that dietary intervention should be considered in all children with
ADHD” (p. 502).
When talking about complementary medicine in ADHD, omega-3
fatty acid supplementation is always a favorite [7•, 36•]. The latter
authors focused on omega-3 with a systematic review and meta-analysis.
Overall, the 10 trials included (n=699 patients) showed a small but
significant constant effect size (SMD=0.31). However with the better
investigated, more effective, and approved psychopharmacological
agents like stimulants and atomoxetine at hand, only an augmentation
seems reasonable. Because of poor quality and weak blinding in earlier
clinical studies, further trials each involving at least 330 children with
ADHD are needed to demonstrate efficacy with an effect size of about
0.3.
Behavioral interventions
In their meta-analytic review on non-pharmacological treatments for ADHD
Hodgson et al. [8•] reported a total of 15 controlled treatment studies con-
ducted between 1994 and 2009. Their latest references stem from 2008 and it
remains unclear, why their publication dated of 2012 neglects the last
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3.5 years of research in the field. The review is further limited by the small
number of studies for each kind of treatment (between 1 and 4) and not
excluding other studies than RCTs. Nevertheless, the evaluation might give a
first critical impression of the basic value of non-pharmacological treatments
for ADHD. To update this impression, the more timely and already sub-
mitted meta-analysis of the Eunethydis ADHD Guidelines Group is urgently
warranted (EAGG submitted).
Considering the overall effect on the range of the reported 20 outcome
measures examined, (eg, ADHD symptoms, other behavior, neuropsycho-
logical test performance, IQ, academic ability). Hodgson et al. [8•] favored
neurofeedback as the most efficacious (average weighted effect size of 0.09),
while behavioral modification, working memory training, school-based
treatment, parent training, and self-monitoring did not show positive average
weighted effect sizes across the outcome measures, reflecting no generalized
greater improvement in the treatment group vs the control group, and thus
might not be deemed efficacious for all parameters investigated.
However, the main purpose of behavioral interventions is to modify be-
havior and self-regulation. From this point of view Hodgson et al. [8•] as-
sume, that mainly behavior therapy and, as a special technique within this
area, neurofeedback may be recommended to treat ADHD.
Two recent narrative reviews confirm the recommendation of neurofeed-
back for ADHD on the basis of the increasing evidence for its short-term
clinical efficacy and stability of treatment effects on ADHD symptoms for at
least 6 months [39••, 40].
Working memory training is another neurotraining but without control-
ling for brain activity. A meta-analytic review on 23 studies concluded that
these programs produce short-term improvement in working memory skills,
which do not generalize to other neuropsychological functions or clearly to
ADHD symptom-reduction. Therefore, this review cast doubt on its clinical
relevance in ADHD [3•].
Since there exist already a multitude of reviews and meta-analyses on
psychosocial treatments for ADHD, the purpose of the systematic ap-
praisal of the evidence by Watson et al. [4••] was to evaluate their
quality in order to refine existing recommendations. Including 13 sys-
tematic reviews and 8 meta-analyses they used the general term of
“psychosocial treatments” to subsume, eg, cognitive-behavioral interven-
tions directly with the child, parent training, behavior modification by
teacher, family counselling, self-regulation methods, EEG-Biofeedback,
and a combination of psychosocial treatments. The highest rated quality
articles noted that pharmacologic plus cognitive-behavioral intervention
(ie, multimodal treatment) had the best benefit for ADHD behaviors and
academic and social outcomes.
Two Cochrane reviews, one on parent training [41•] and another one on
social skills training [42] added to this conclusion, that parent training might
have a positive effect on the behavior of children with ADHD (especially
preschool children), but the evidence from this review is not strong enough
to form a basis for clinical practice guidelines. For social skills training there
is little evidence (ie, no statistically significant treatment effects on social
skills competence, general behavior or ADHD symptoms) and lacking of
non-biased data. This leaves it open what to recommend.
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Further studies which try to test combined parent and teacher/child psy-
chosocial treatment programs are ongoing with some preliminary success
mainly on children’s externalizing behavior [43, 44]). With all these psy-
chosocial treatments in mind it seems highly important to consider the in-
fluence of parental ADHD [45] and, related to this, also the genetic
background of the child and the parents [46].
Treating comorbidity
In ADHD, comorbidity is the rule (60 %–80 %) and, psychosocially, the
most impairing disorder needs to be treated first, but sometimes the co-
occurring problems need to be treated in parallel [47]. The guidelines of the
American Academy of Pediatrics ([10••], (p. 1019) state: “The effect of co-
existing conditions on ADHD treatment is variable. In some cases treatment
of the ADHD resolves the co-existing condition. For example, treatment of
ADHD might resolve oppositional defiant disorder or anxiety. However,
sometimes the co-occurring condition might require treatment that is in
addition to the treatment of ADHD” (eg, neuroleptics for tic disorders; SSRI
for depression; behavior therapy for obsessive-compulsive disorder, or sub-
stance use disorder). There is no question that in the case of comorbidity
ADHD symptoms may be successfully treated with stimulants or atomoxe-
tine or clonidine [48, 49]. Clinical practice reflects that use of psychotropic
medication for ADHD with co-existing disorders is wide spread. Frazier et al.
[50] reported of the first wave of a USA-wide representative study of ado-
lescents aged 13–17 in special education. Youths with autism spectrum dis-
order (ASD) plus ADHD had a rate of 58 %, those with ADHD-only 49 %
and youths with ASD-only 34 %. As expected, in patients with ADHD-only
stimulants were dominant, while the 2 ASD-groups used medication across a
variety of medication classes depending on associated symptoms. In about
30 % of comorbid cases more than 2 medications were taken. This raises 2
unresolved questions. First, the evidence is low for studies with combined
medication. For example, in a secondary analysis of a study with ADHD in
adults, Biederman et al. [51] concluded that they found no moderating
effects of concomitant use of antidepressants on the ADHD treatment effect
with OROS-MPH. Second, a paucity of data exists also for the evidence re-
lated to the combined use of medication and psychotherapy (eg, [52]).
In summary, studies on efficacy, effectiveness, and safety of poly-pharma-
cy in ADHD comorbidity are needed to provide a better empirical guideline
for the widespread use of multiple medications, often in combination with
psychotherapy.
Ethical considerations
There exists an ongoing ethical discussion about how the physician should
handle treatment when sharing and selling of prescribed stimulants may play
a role. Especially, when these drugs are used to treat patients with ADHD
plus a substance use disorder (SUD). Diversion of stimulants varies across
adolescent populations and shows the highest prevalence among ADHD
patients using other illicit drugs [53]. Fortunately, “concerns that these
practices have become more prevalent as a result of increased prescribing are
not supported by large-scale population surveys” [53]. Further, with close
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monitoring stimulants can be safely used to treat ADHD and reduce co-
existing substance abuse. However, since prescription stimulants diverters
have more childhood conduct problems than non-diverters, this area of
developmental psychopathology needs special attention within a treatment
program for ADHD plus SUD including stimulant prescription [54, 55].
Another point of on-going ethical controversy is a probable pharma-
cological neuroenhancement (doping for performance) in ADHD. Neu-
roenhancement (and probably related to this faking ADHD) is merely a
problem of adults [56–58], especially in cases where the diagnostic cri-
teria according to DSM-IV and ICD-10 are not or not completely ful-
filled but symptom-related psychosocial impairment hinders the child’s
development.
This discussion includes different views on ADHD concerning, eg, in-
clusion/exclusion criteria, the question of dimensionality vs categoriza-
tion, validity, and reliability of diagnostics in clinical practice and, thus,
the sound empirical and practical basis for clear treatment decisions in
contrast to hidden neuroenhancement within a grey zone of diagnostics
[59].
Ethical problems and controversies could be minimized if a nor-
malization of Quality of Life in patients with ADHD and their fami-
lies [60] would be accepted as the goal for treatment decisions. The
latter should be made along the ADHD guidelines available [2, 10••]
and should include a critical evaluation and monitoring of the psy-
chosocial context in order to avoid medication of problems, which
may be solved otherwise.
ADHD can be a lifelong threat starting early in life with long-term treat-
ments of different kind. Unfortunately, medication nonadherence seems to
be common in childhood/adolescent ADHD [61]; thus, it is an ethical
challenge for the physician to improve compliance within the process of
diagnosis and treatment. Therefore, it is important that the child/adolescent
is always involved in the assent/informed consent process as fully as possi-
ble. Such a process, which should be revisited over time, should also have a
scientific empirical basis as the treatment itself. Data are scarce and, there-
fore, the article of Schachter et al. [62] is welcome. They focused on the
understanding of information necessary to consent the treatment with
stimulant medication. Fifty-eight ADHD and 64 control adolescents (12–
16 years of age) and their parents were studied with interviews and ques-
tionnaires. Knowledge and, thus, the basic precondition for informed con-
sent were increased after the information session for all subjects. The study
has shown that adolescents can gain the capacity to consent after adequate
information about benefits and risks of stimulants. Their understanding is
similar to that of their parents. Thus, the adolescents` inclusion and rein-
forcement of their autonomic decision in this consensual process should be
regarded.
Close to this process is the ethical impetus to increase shared deci-
sion-making in ADHD [63•, 64•]. Shared decision-making (SDM) is
ethically recommended in general but it is of particular importance when
multiple evidence-based treatments exist and parents, patients, and
clinicians value the available options differently as in these situations
there is a great potential for conflicts and misunderstanding. Little em-
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pirical research is known about the process coming up afterwards and
what kind of solution and under which conditions it will be reached.
Fiks et al. [65] conducted interviews with 60 parents of children with
ADHD (6–12 years of age) and 30 primary care clinicians. Parents and
clinicians both viewed SDM favorably, but they understood SDM dif-
ferently. Pediatric clinicians often tried to persuade families to accept
their preferred treatment while parents desired objective and well based
information before decision-making, even if they ultimately delegated
responsibility for the decision to the clinician [63•, 65]. Such a disparity
may influence adherence and revisitation of SDM over time as families
acquire real-world experience and new problems have to be discussed.
Finally, public health conditions (eg, time and reimbursement available)
may modify SDM and its ethical implications. SDM-implications for
clinical practice depend highly on such profane issues.
The handling of children’s willingness to use ADHD treatments, medica-
tion refusal, and their developmentally adequate self-management of medi-
cation are also important issues for ethical considerations, since they are
closely related to compliance and adherence, ie, the success of treatment with
good psychosocial functioning giving the youngster a better chance for his/
her future. This seems to be ethically important with regard to prevention of
severe symptoms, adverse events concerning high dosages of medication, and
difficulties in social life.
Summarizing the following empirical publications of Bussing et al. [66],
Brinkman et al. [67], and Demidovich et al. [68], one can say that the dif-
ferent roles of patients and parents along the lifespan and along the course of
ADHD have to be interactively guided by the specialist, (eg,. ensuring a de-
velopmentally appropriate transition from family- to self-management of
ADHD and its treatment). In particular, adolescents’ perceptions of unde-
sirable effects, like stigma, related to ADHD should be openly discussed [49,
69]. A quality improvement in community-based pediatric ADHD care along
the guidelines could further contribute to optimize ADHD interventions [70•].
Perspectives
Within the last 2 years, the bulk of studies on ADHD treatment could be
reviewed to get their essential content and usefulness for further clinical practice
including prevention. A broad variety of evidence-based treatments is available
like behavior therapy, neurofeedback, family coaching, and psychopharmacol-
ogy. As the combination of treatments seems to be clinically and ethically rec-
ommended, studies of combined treatment are needed to clarify which profile
of multimodal treatment fits best the needs of families with an ADHD patient.
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